Evidence map›Paper›PMID 34980789›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2022

Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma.

Naoki Takahashi, Kunihiro Tsukasaki, Ken Tanae, Mika Kohri, Chie Asou, Daisuke Okamura, Maho Ishikawa, Tomoya Maeda, Nobutaka Kawai, Akira Matsuda and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. RB and CHASER as induction therapy for transplant-eligible mantle cell lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Naoki TakahashiDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Kunihiro TsukasakiDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Ken TanaeDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Mika KohriDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Chie AsouDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Daisuke OkamuraDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Maho IshikawaDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Tomoya MaedaDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Nobutaka KawaiDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Akira MatsudaDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Tsugumi SatoDepartment of Pathology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Hidekazu KayanoDepartment of Pathology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Eiichi AraiDepartment of Pathology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Norio AsouDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Saitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bendamustine is now recognized as a key drug for indolent B-cell lymphoma (iBCL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Skin toxicity associated with bendamustine is one of the characteristic adverse effects. We retrospectively examined the relationship between bendamustine-associated drug rashes and disease prognosis of iBCL and MCL at our institution. Between January 2011 and August 2019, 65 patients (39 men and 26 women, median age 68, range 41-84 years) were treated with bendamustine alone (n=11, 120 mg/m

Indexed as

ExanthemaLymphoma, B-CellAdultAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideFemaleHumansPrognosisRetrospective StudiesRituximabBendamustine HydrochlorideRituximabBendamustine-induced rashFavorable prognosisIndolent B-cell lymphomaMantle cell lymphoma

Identifiers

PMID34980789
PMCPMC9010495
OpenAlexW4206593131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.